A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients With Idiopathic Pulmonary Fibrosis, Open Label Extension.

Trial Profile

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients With Idiopathic Pulmonary Fibrosis, Open Label Extension.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 23 Feb 2012

At a glance

  • Drugs Bosentan (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Therapeutic Use
  • Acronyms BUILD-1
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 23 Feb 2012 Actual initiation date (Aug 2003) added as reported by ClinicalTrials.gov.
    • 23 Feb 2012 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
    • 23 Feb 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT00071461).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top